Letrozole
-
- 应用范围
- Inhibition Assay (InhA), Functional Studies (Func)
- 原理
- Letrozole (INN, trade name Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production. Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax. Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems. Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature.
- 产品特性
-
Tradename: FEMARA
Source of Compound: synthetic
Target: Aromatase Inhibitor
Receptor: Aromatase
- 纯化方法
- All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
- 纯度
- 98 %
- Formula
- C17H11N5
- Solubility
- Soluble in water
-
Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
RadicicolInh 12772-57-5
Geldanamycin- FITCInh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
PanobinostatInh 404950-80-7 (E)-N-Hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
HPA (Hexyl-4-pentynoic acid)Inh Cell-permeable 96017-59-3 2-(2-Propynyl)octanoic acid (racemic)
EX-527Inh Cell-permeable 49843-98-3 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-xarboxamide (racemic)
DaminozideInh 1596-84-5 1-(2,2-Dimethylhydrazide)butanedioic acid
Mithramycin AInh 18378-89-7
PiceatannolInh 10083-24-6 3,3',4,5'-Tetrahydroxy-trans-stilbene
Santacruzamate AInh 1477949-42-0 N-[4-Oxo-4-[(2-phenylethyl)amino]butyl]-carbamic acid, ethyl ester
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 状态
- Solid
- 储存条件
- -20 °C
- 储存方法
-
For the majority of compounds, they could be dissolved in DMSO or other organic solvent.
Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience.
Several freeze/thaw cycles should not damage the activity of our small molecule products.
However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours. - 有效期
- 24 months
-
- 背景
- Endocrinology/ Hormones
- 分子量
- 285.30 g/mol
- CAS-编号
- 112809-51-5
-
